Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

Cancer Letters

Volumn 360, Issue 2, 2015, Pages 302-309

  Xiao, Zhenyu ^a   Chung, Haniee ^a   Banan, Babak ^a   Manning, Pamela T ^b   Ott, Katherine C ^a   Lin, Shin ^c   Capoccia, Benjamin J ^a   Subramanian, Vijay ^a   Hiebsch, Ronald R ^b   Upadhya, Gundumi A ^a   Mohanakumar, Thalachallour ^a   Frazier, William A ^a   Lin, Yiing ^a   Chapman, William C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vasculox Inc   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Antibody therapy; CD47; HCC; Xenograft models

Indexed keywords

ANTINEOPLASTIC AGENT; B 6 H 12; CD47 ANTIGEN; CD47 MONOCLONAL ANTIBODY 400; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD47 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL INFILTRATION; CELL MIGRATION; CELL PHAGOCYTOSIS; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DRUG SCREENING; HEPG2 CELL LINE; IMMUNOLOGY; LIVER NEOPLASMS; PHAGOCYTOSIS; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD47; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MACROPHAGES; MALE; MICE; MICE, SCID; PHAGOCYTOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924908589     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.036     Document Type: Article

References (14)

1. Thomas M.B., Jaffe D., Choti M.M., Belghiti J., Curley S., Fong Y., et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol 2010, 28:3994-4005. 10.1200/JCO.2010.28.7805.
2. Tsai R.K., Discher D.E. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol 2008, 180:989-1003. 10.1083/jcb.200708043.
3. Latour S., Tanaka H., Demeure C., Mateo V., Rubio M., Brown E.J., et al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J. Immunol 2001, 167:2547-2554. accessed 08.23.14. http://www.ncbi.nlm.nih.gov/pubmed/11509594.
4. Braun D., Galibert L., Nakajima T., Saito H., Quang V.V., Rubio M., et al. Semimature stage: a checkpoint in a dendritic cell maturation program that allows for functional reversion after signal-regulatory protein-alpha ligation and maturation signals. J. Immunol 2006, 177:8550-8559. accessed 08.23.2014. http://www.ncbi.nlm.nih.gov/pubmed/17142753.
5. Lee T.K.W., Cheung V.C.H., Lu P., Lau E.Y.T., Ma S., Tang K.H., et al. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014, 60(1):179-191. 10.1002/hep.27070.
6. Kwong L.S., Brown M.H., Barclay A.N., Hatherley D. Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells. Immunology 2014, 143:61-67. 10.1111/imm.12290.
7. Pinheiro J., Bates D. Mixed-Effects Models in S and S-PLUS 2009, Springer Verlag, New York.
8. Kuang D.-M., Wu Y., Chen N., Cheng J., Zhuang S.-M., Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007, 110:587-595. 10.1182/blood-2007-01-068031.
9. Newell P., Villanueva A., Friedman S.L., Koike K., Llovet J.M. Experimental models of hepatocellular carcinoma. J. Hepatol 2008, 48:858-879. 10.1016/j.jhep.2008.01.008.
10. Edris B., Weiskopf K., Volkmer A.K., Volkmer J.-P.J.-P., Willingham S.B., Contreras-Trujillo H., et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6656-6661. 10.1073/pnas.1121629109.
11. Willingham S.B., Volkmer J.-P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6662-6667. 10.1073/pnas.1121623109.
12. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbé C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624.
13. Soto-Pantoja D.R., Terabe M., Ghosh A., Ridnour L.A., DeGraff W.G., Wink D.A., et al. CD47 in the tumor microenvironment limits cooperation between antitumor t-cell immunity and radiotherapy. Cancer Res 2014, 74:6771-6783. 10.1158/0008-5472.CAN-14-0037-T.
14. Tseng D., Volkmer J.-P., Willingham S.B., Contreras-Trujillo H., Fathman J.W., Fernhoff N.B., et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:11103-11108. 10.1073/pnas.1305569110.